RBC
EW icon

Roble Belko & Company’s Edwards Lifesciences EW Stock Holding History

Roble Belko & Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Hold
618
– – 0.01% 203
2026
Q1 		$49K Hold
618
– – 0.01% 206
2025
Q4 		$53K Hold
618
– – 0.01% 201
2025
Q3 		$48K Hold
618
– – 0.01% 177
2025
Q2 		$48K Hold
618
– – 0.01% 177
2025
Q1 		$45K Hold
618
– – 0.01% 177
2024
Q4 		$46K Buy
+618
New +$43.3K 0.01% 170

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Roble Belko & Company's EW Position: Q2 2026 in Review

Roble Belko & Company held its Edwards Lifesciences (EW) position steady in Q2 2026 at 618 shares worth $56K. The position accounts for 0.01% of the portfolio, ranked #203.

Roble Belko & Company first reported a position in EW in Q4 2024 and has held it in 7 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Roble Belko & Company held 618 shares of Edwards Lifesciences worth $56K as of Q2 2026.
  • Roble Belko & Company left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.01% of Roble Belko & Company's portfolio in Q2 2026, its #203 holding.
  • Roble Belko & Company first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.